DanVladIosifescuMD

Psychiatry • New York, NY

Professor of Psychiatry, NYU School of Medicine and Director, Clinical Research Division, Nathan Kline Institute

Join to view full profile

Dr. Iosifescu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Iosifescu's full profile

Already have an account?

Office
1 Park Ave
Fl 8
New York, NY 10016
Phone+1 212-263-7419

Summary

Dr. Dan Iosifescu is a psychiatrist in New York, NY and is affiliated with NYU Langone Health. He received his medical degree from Carol Davila University of Medicine and Pharmacy and has been in practice 33 years. His clinical expertise is primarily focused on mood disorders ((bipolar disorder, treatment-resistant depression). His research is focused on novel pharmacological treatments (such as ketamine and other glutamatergic drugs) and devices (such as photobiomodulation with near infrared light and novel forms of magnetic stimulation) for patients with severe mood disorders and Alzheimer's disease. In his research Dr. Iosifescu uses neuroimaging (MRI, MRS, PET) and neurophysiology (quantitative EEG) techniques to evaluate structural, biochemical, and functional brain abnormalities and their impact on clinical treatment. Dr. Iosifescu has more than 200 publications and over 500 abstracts.

Education & Training

Harvard Medical School and Massachusetts Institute of TechnologyMaster of Medical Science (M.M.Sc.), Clinical Investigation, 2001 - 2003
Massachusetts General Hospital/McLean HospitalResidency, Psychiatry, 1997 - 2000
Massachusetts General HospitalInternship, Internal Medicine, 1996 - 1997
Carol Davila University of Medicine and PharmacyClass of 1992

Certifications & Licensure

FL State Medical License 2022 - Present
MA State Medical License 1998 - 2025
NY State Medical License 2009 - 2025
American Board of Psychiatry and Neurology Psychiatry

Clinical Trials

Quantitative EEG (QEEG) as a Predictor of Treatment Outcome in Depression Start of enrollment: 2003 Apr 01
Completed
Phase 4
Galantamine-CR and Cognitive Dysfunction in Bipolar Disorder
Completed
Not Applicable
Brain Energy Metabolism in Individuals With Major Depressive Disorder Receiving Escitalopram Start of enrollment: 2003 Jul 01
Completed
Phase 4
Brain GABA Levels and Treatment Response in Major Depressive Disorder Start of enrollment: 2006 Sep 01
Completed
Phase 4
Biochemical Brain Changes Correlated With The Antidepressant Effect Of Thyroid Hormones Start of enrollment: 2001 Oct 01
Completed
Not Applicable
Efficacy and Safety of Galantamine for Improving Dysfunction in People With Bipolar Disorder Start of enrollment: 2008 Sep 01
Completed
Phase 4
Optimization of IV Ketamine for Treatment Resistant Depression Start of enrollment: 2008 Nov 01
Completed
Phase 2
Minocycline for Bipolar Depression Start of enrollment: 2011 May 01
Completed
Phase 4
Safety and Efficacy Study of Deep Transcranial Magnetic Stimulation in Bipolar Depression Start of enrollment: 2012 May 01
Unknown status
Not Applicable
Trial of Low Field Magnetic Stimulation Augmentation of Antidepressant Therapy in Treatment-Resistant Depression Start of enrollment: 2013 Apr 01
Completed
Not Applicable
Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD) Start of enrollment: 2014 Dec 01
Completed
Phase 2
Evaluation of Deep Transcranial Magnetic Stimulation (DTMS) With the H-ADD Coil as an Aid to Smoking Cessation. Start of enrollment: 2014 Aug 20
Completed
Phase 3
Transcranial Laser Therapy, Continuous and Pulsed Light, for Major Depressive Disorder (ELATED-3) Start of enrollment: 2016 Nov 01
Completed
Not Applicable
Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD Start of enrollment: 2017 May 01
Completed
Phase 4
Biomarkers of Response to Ketamine in Depression: MRI and Blood Assays Before and After Open Label Intranasal Ketamine Start of enrollment: 2019 Jun 26
Completed
Phase 2, Phase 3
Transcranial Near Infrared Radiation and Cerebral Blood Flow in Depression Start of enrollment: 2020 Aug 01
Completed
Not Applicable
Join now to see all

Publications & Presentations

PubMed

Understanding the relationship between childhood abuse and affective symptoms in bipolar disorder: New insights from a network analysis.
Anna L Wrobel, Megan Turner, Olivia M Dean, Michael Berk, Louisa G Sylvia
Psychiatry Research. 2024-12-01
Transcranial photobiomodulation: an emerging therapeutic method to enhance brain bioenergetics.
Naomi L Gaggi, Dan V Iosifescu
Neuropsychopharmacology. 2024-11-01
Dose-dependent effects of transcranial photobiomodulation on brain temperature in patients with major depressive disorder: a spectroscopy study.
Akila Weerasekera, David Richer Araujo Coelho, Eva-Maria Ratai, Katherine Anne Collins, Aura Maria Hurtado Puerto
Lasers in Medical Science. 2024-10-07

Journal Articles

Effects of the KCNQ Channel Opener Ezogabine on Functional Connectivity of the Ventral Striatum and Clinical Symptoms in Patients with Major Depressive Disorder
Katherine A Collins, Dan V Iosifescu, James W Murrough, Eric J Nestler, Nisha Chadha, Nature
Double-Blind, Placebo-Controlled, Dose-Ranging Trial of Intravenous Ketamine as Adjunctive Therapy in Treatment-Resistant Depression (TRD)
Sanjay J Mathew, Madhukar H Trivedi, Lee C Chang, Dan V Iosifescu, Manish K Jha, Maurizio Fava, Marlene P Freeman, Cristina Cusin, James Murrough, George I Papakostas,..., Nature

Authored Content

Dopamine Release in Antidepressant-Naïve Major Depressive Disorder: A Multimodal [11C]-(+)-PHNO Positron Emission Tomography and Functional Magnetic Resonance Imaging StudyMay 2018
Dopamine Release in Antidepressant-Naïve Major Depressive Disorder: A Multimodal [11C]-(+)-PHNO Positron Emission Tomography and Functional Magnetic Resonance Imaging StudyMay 2018
F179. Epigenetic Biomarkers in Women with Posttraumatic Stress Disorder After CRF1 Receptor Antagonist TreatmentApril 2018
F179. Epigenetic Biomarkers in Women with Posttraumatic Stress Disorder After CRF1 Receptor Antagonist TreatmentApril 2018
Join now to see all

Press Mentions

Axsome Therapeutics Receives FDA Nod for AuvelitySeptember 7th, 2022
FDA Approves First Fast-Acting Oral Drug for Clinical Depression That Works in 1 WeekAugust 25th, 2022
Does Pharmacogenomic Testing Improve Outcomes in Major Depressive Disorder?July 12th, 2022
Join now to see all

Grant Support

Efficacy And Safety Of Galantamine For Dysfunction In Bipolar DisorderNational Institute Of Mental Health2010–2011
Efficacy And Safety Of Galantamine For Dysfunction In Bipolar DisorderNational Institute Of Mental Health2008–2009
Depression And Brain MetabolismNational Institute Of Mental Health2003–2007